We here provide evidence that CD169+ TAMs associate with TLLS, Treg and Breg signatures in breast cancers, leading to an adverse clinical outcome when present in PTs, while the opposite effect was observed in LNMs. The gene discussed is SIGLEC1; the disease is breast carcinoma.